BeStock  
Stocks › Biotechnology › PBLS

Parabilis Medicines PBLS

US equityMarket cap rank #2333Biotechnology
$27.44 −$0.19 (-0.67%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $27.44 0.00%
Open$27.07
Prev close$27.63
Day range$26.50 – $28.52
Volume1.25M
Market cap$3.44B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$148,000.00
Operating profit-$50.89M-39.3% YoY
Net profit-$52.46M-50.7% YoY
Diluted EPS-$2.32-314.6% YoY
Free cash flow-$4.24M+86.4% YoY
Operating cash flow-$3.62M

Revenue, last 4 quarters

$0.0Mar '25$0.0Jun '25$0.0Mar '26$148.0KJun '26

Net profit, last 4 quarters

$-38.3MMar '25$-34.8MJun '25$-45.3MMar '26$-52.5MJun '26

Diluted EPS by quarter

-0.60Mar '25-0.56Jun '25-0.56Mar '26-2.32Jun '26

Free cash flow by quarter

$-34.2MMar '25$-31.1MJun '25$-49.6MMar '26$-4.2MJun '26

Profitability & balance sheet

Operating margin-117,335.8%
Net margin-156,531.8%
Return on equity-22.1%
Return on assets-19.7%
Return on invested capital-21.7%
Current ratio17.91
Liabilities / assets10.9%
Cash & investments$1.12B
Total debt$39.25M
Net cash (debt)$1.08B

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2024 ANNUAL
Other Current Assets $4.70M $3.03M $1.65M $3.87M
Payables $18.53M $15.25M $17.27M $9.51M
-Accounts Payable $18.53M $15.04M $17.27M $9.51M
Current Accrued Expenses $10.29M $13.94M $8.33M $6.55M
Short-Term Debt and Capital Lease Obligation $13.97M $17.43M $20.89M $9.38M
-Current Debt $5.71M $9.40M $13.08M $2.50M
-Current Capital Lease Obligation $8.26M $8.03M $7.81M $6.88M
Current Deferred Liabilities $10.37M – – –
Total Current Liabilities $62.84M $54.24M $56.79M $32.41M
Total Liabilities $127.53M $139.95M $97.34M $92.81M
Total Assets $1.18B $384.17M $80.82M $149.25M
Total Current Assets $1.13B $332.07M $29.36M $92.21M
Cash and Cash Equivalents & Short-Term Investments $1.12B $329.04M $27.71M $87.98M
-Cash and Cash Equivalents $1.09B $329.04M $27.71M $47.28M
-Short Term Investments $33.64M – $0.00 $40.69M
Total Non-Current Assets $49.87M $52.10M $51.46M $57.05M
Net PPE $42.73M $44.36M $46.08M $52.93M
-Gross PPE $56.69M $57.73M $58.89M $63.38M
-Accumulated Depreciation -$13.97M -$13.38M -$12.81M -$10.45M
Other Non-Current Assets $7.14M $7.75M $5.39M $4.12M
Long Term Debt and Capital Lease Obligation $33.54M $35.71M $37.81M $56.82M
-Long Term Capital Lease Obligation $33.54M $35.71M $37.81M $44.03M
Non-Current Deferred Liabilities $31.15M – – –
Total Equity $1.05B $244.22M -$16.52M $56.44M
Stockholders' Equity $1.05B $244.22M -$16.52M $56.44M
Capital Stock $12,000.00 $814.54M $509.97M $440.38M
-Common Stock $12,000.00 $0.00 $0.00 $0.00
-Preferred Stock $0.00 $814.54M $509.97M $440.38M
Additional Paid-In Capital $1.69B $16.50M $15.01M $11.66M
Retained Earnings -$639.28M -$586.82M -$541.50M -$395.62M
Other Current Liabilities $4.23M $3.88M $1.22M $622,000.00
Total Non-Current Liabilities $64.69M $85.71M $40.55M $60.40M
Gains/Losses Not Affecting Retained Earnings -$18,000.00 – $0.00 $21,000.00
Derivative Product Liabilities – $50.00M – –
-Due to Related Parties Current – $211,000.00 – –
Receivables – – $0.00 $360,000.00
-Due from Related Parties Current – – $0.00 $360,000.00
Convertible preferred securities – – $0.00 $2.17M
Other Non-Current Liabilities – – $2.74M $1.41M
-Long Term Debt – – – $12.79M

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q2 2025 Q1
Total Revenue as Reported $148,000.00 – – $0.00 –
Total Operating Revenue $148,000.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $51.03M $47.45M $152.08M $36.52M $40.24M
Selling and Admin Expenses $11.66M $9.70M $26.50M $6.39M $6.34M
Net Non-Operating Interest Income (Expense) $3.98M $2.14M $1.86M $653,000.00 $858,000.00
-General & Admin Expense $11.66M $9.70M $26.50M $6.39M $6.34M
Research & Development $39.38M $37.75M $125.58M $30.13M $33.91M
Operating Profit -$50.89M -$47.45M -$152.08M -$36.52M -$40.24M
Diluted EPS -$2.32 -$0.56 -$1.81 -$0.56 -$0.60
Basic EPS -$2.32 -$0.56 -$1.81 -$0.56 -$0.60
Non-Operating Interest Income $4.19M $2.43M $3.39M $1.05M $1.26M
Non-Operating Interest Expense $210,000.00 $292,000.00 $1.52M $396,000.00 $399,000.00
Other Income (Expense) -$5.56M – $4.33M $1.06M $1.06M
Other Non-Operating Income (Expenses) -$5.56M – $4.33M $1.06M $1.06M
Net Profit -$52.46M -$45.32M -$145.89M -$34.81M -$38.33M
Profit from Continuing Operations -$52.46M -$45.32M -$145.89M -$34.81M -$38.33M
Net Income to Parent Company -$52.46M -$45.32M -$145.89M -$34.81M -$38.33M
Preferred Stock Dividends $14.49M $25.56M $41.04M $10.18M $9.78M
Net Income to Common Stockholders -$66.96M -$70.88M -$186.93M -$44.99M -$48.11M
Pretax Profit -$52.46M -$45.32M -$145.89M -$34.81M -$38.33M

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q2 2025 Q1
-Change in Receivables $0.00 $0.00 $360,000.00 $96,000.00 $75,000.00
Net Income from Continuing Operations -$52.46M -$45.32M -$145.89M -$34.81M -$38.33M
Free Cash Flow -$4.24M -$49.57M -$124.02M -$31.11M -$34.23M
Beginning Cash Balance $331.89M $30.57M $50.14M $89.96M $50.14M
Net Change in Cash $758.02M $301.33M -$19.57M -$6.71M $39.82M
Ending Cash Balance $1.09B $331.89M $30.57M $83.25M $89.96M
Net Other Financing Charges -$2.54M $49.37M – $0.00 -$62,000.00
Proceeds from Stock Option Exercised $584,000.00 $187,000.00 $34,000.00 $9,000.00 $0.00
Net Preferred Stock Issuance $0.00 $305.25M $67.43M $0.00 $67.49M
Net Issuance Payments Of Debt -$3.91M -$3.90M -$3.08M -$144,000.00 -$140,000.00
Net Cash Flow from Continuing Financing Activities $795.71M $350.90M $64.38M -$135,000.00 $67.29M
Financing Cash Flow $795.71M $350.90M $64.38M -$135,000.00 $67.29M
Net Investment Purchase and Sale -$33.45M $0.00 $40.06M $24.53M $6.76M
Net PPE Purchase and Sale -$616,000.00 -$369,000.00 -$306,000.00 -$16,000.00 -$74,000.00
Other Non-Cash Items $1.75M $1.74M $6.63M $1.62M $1.61M
Depreciation & Depletion & Amortization $593,000.00 $606,000.00 $2.50M $618,000.00 $654,000.00
Operating Cash Flow -$3.62M -$49.20M -$123.71M -$31.09M -$34.15M
Change in Working Capital $37.52M -$7.53M $9.12M $370,000.00 $871,000.00
-Change in Prepaid Assets -$2.55M -$2.81M $1.51M $1.20M -$1.13M
Net cash flow from continuing operations -$3.62M -$49.20M -$123.72M -$31.09M -$34.15M
-Change in Payables and Accrued Expense $337,000.00 -$3.00M $13.59M $645,000.00 $3.44M
-Change in Other Current Liabilities -$1.79M -$1.72M -$6.34M -$1.57M -$1.51M
Net cash flow from investing -$34.06M -$369,000.00 $39.76M $24.51M $6.69M
Net Cash Flow from Continuing Investing Activities -$34.06M -$369,000.00 $39.76M $24.51M $6.69M

Discussion

No comments yet — be the first to weigh in on PBLS.

Sign in to join the discussion.

Scroll to Top